The ACIP panel voted to recommend that 18 years and older individuals with certain risk factors should be administered a two-dose regimen of the vaccine
Jynneos was developed by Bavarian Nordic in collaboration with the US government. (Credit: Desiré 🙏 Dazzy 🎹🎶 K-e-k-u-l-é from Pixabay)
Bavarian Nordic said that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the routine use of the Jynneos vaccine in adults at risk of mpox infection.
Jynneos (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) was developed by Denmark-based Bavarian Nordic in collaboration with the US government.
It was originally approved to prevent smallpox and mpox disease in adults aged 18 years and older and found at high risk for smallpox and mpox infection.
The ACIP panel voted to recommend that 18 years and older individuals with certain risk factors should be administered a two-dose regimen of the vaccine.
Previously, the Advisory Committee recommended Jynneos for those at risk of mpox only during an outbreak.
The US Department of Health and Human Services and the Director of the CDC will examine the recommendations before they are published in the Morbidity and Mortality Weekly Report once they have been approved.
Bavarian Nordic president and CEO Paul Chaplin said: “The broadened ACIP recommendation recognises the significance of maintaining a high awareness of the disease among risk groups and the importance of ensuring broader access to the vaccine beyond an outbreak situation.
“Entering the private mpox vaccine market in the US offers an opportunity to provide improved access to Jynneos and to build a steady commercial business segment, complimenting existing smallpox stockpiling business with the US government.
“With our unwavering commitment to improving public health, we look forward to working with healthcare professionals to make our vaccine available for all individuals at risk.”
This is the second national recommendation for adult risk categories for the mpox vaccine from the vaccine company, which comes after a similar recommendation made in 2022 by the German Standing Committee for Vaccination (STIKO).
The European AIDS Clinical Society (EACS) has recently recommended the vaccine for adults living with HIV or receiving pre-exposure prophylaxis (PrEP) treatment.
In the first half of 2024, Bavarian Nordic plans to commercially introduce Jynneos in the US, once the updated recommendations are approved.